Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(13 sites)
China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong Public Health Institute of Sun Yat-sen University, Guangzhou, Guangdong Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong Sun Yat-sen University Cancer Center, Guangzhou, Guangdong The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Shantou Central Hospital, Shantou, Guangdong Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, Guangdong Shenzhen People's Hospital, Shenzhen, Guangdong Affiliated Hospital of Guangdong Medical University, Zhangjiang, Guangdong Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, Guangdong Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi Hunan Cancer Hospital, Changsha, Hunan Last updated September 2022